allogene
An Executive Director, Market Access at Allogene Therapeutics defines and leads global market access strategy for allogeneic CAR T therapies. This role focuses on pricing, payer engagement, reimbursement, and patient access while collaborating with cross-functional teams to shape value propositions and access strategies.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2017
Allogene is a clinical-stage biotechnology company developing off-the-shelf AlloCAR T cell therapies using multiplex gene engineering and gene-editing to create allogeneic (ready-made) CAR T candidates. The company pairs a proprietary lymphodepletion approach with scalable, state-of-the-art manufacturing to optimize safety, durability, and broader patient access. Lead programs include cemacabtagene ansegedleucel (cema‑cel) for large B‑cell lymphoma (including frontline DLBCL), ALLO‑316 for renal cell carcinoma, and ALLO‑329 for autoimmune disease, alongside a broader pipeline. Allogene’s platform strategy aims to accelerate delivery of cell therapies by removing patient-specific manufacturing constraints.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for allogene.
Director, Global Pricing and Market Access Strategy Lead Immunology
Bristol Myers Squibb
(Senior) Pricing and Access Manager - Oncology
Digital Biology
Market Access and Government Affairs Lead Bulgaria
Medtronic
Director, International Market Access, Neuroscience, Parkinson's
AbbVie
Director, Payer Access
Grunenthal
Senior Director, Market Access Strategy
Amylyx Pharmaceuticals